HR, hazard ratio; OR, overall response; CR, complete response; Neu, neutropenia; Throm, thrombocytopenia; Anae, anaemia; Sep, neutropenic sepsis; Muc, mucositis; Leuc, leucopenia; Neuro, neurotoxicity; SAT, severe acute toxicity; Stoma, stomatitis; Gran, granulocytopenic fever
| Study/ comparators | Overall survival | Progression-free survival | Grade 3-4 toxicities, % | Other, % | Quality of life | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rate, % | Median months | HR (95% CI) | Rate, % | Median months | HR (95% CI) | Neu | Throm | Anae | SAT | Sep | Muc | Toxic deaths (n) | ||
| von der Maase (2005) | 5 yrs | 5 yrs | QoL maintained over time on both arms, improved emotional functioning and pain. | |||||||||||
| GC (n=203) | 13.4 | 14.0 | 1.09 (0.88-1.34) | 9.4 | 7.7 | 1.09 (0.89-1.34) | 71 | 57 | 27 | 1 | 1 | 1% | ||
| vs. MVAC (n=202) | 15.3 | 15.2 | p=0.66 | 11.9 | 8.3 | p=0.63 | 82 | 82 | 17 | 12 | 22 | 3% | ||
| Bellmunt (2012) | 4.6 yrs | 4.6 yrs | ||||||||||||
| PCG (n=312) | 20 | 15.8 | 0.85 (0.72-1.02) | 14 | 8.3 | 0.87 (0.74-1.03) | 64 | 35 | 20 | 6 | ||||
| vs. GC (n=314) | 18 | 12.7 | p=0.75 | 11 | 7.6 | p=0.113 | 51 | 52 | 15 | 3 | ||||
| Bellmunt (2012) | Primary bladder tumours only | |||||||||||||
| PCG (n=254) | 15.9 | 0.80 (0.66-0.97) | ||||||||||||
| vs. GC (n=259) | 11.9 | p=0.025 | ||||||||||||
| Lorusso (2005) | ||||||||||||||
| Leuc | Neuro | |||||||||||||
| GC (n=43) | 12.3 | 33 | 6.5 | 35 | 21 | 24 | 5 | 5 | ||||||
| vs. PCG (n=42) | 15.3 | 29 | 8 | 49 | 36 | 20 | 0 | 0 | ||||||
| Bamias 2004 | ||||||||||||||
| MVAC +GCSF (n=109) | 32 | 14.2 | 1.52 (1.11-2.08) | 9.4 | 1.73 (1.24-2.42) | 36 | 6 | 8 | 12 | 2 | ||||
| vs. DC +GCSF (n=111) | 24 | 9.3 | p=0.0255 | 6.1 | p=0.0029 | 19 | 1 | 6 | 4 | 1 | ||||
| Sternberg 2006 | 7.3 yrs | 7.3 yrs | ||||||||||||
| Fever | WBC | |||||||||||||
| HD-MVAC (n=134) | 24.6 | 15.1 | 0.76 (0.58-0.99) | 18.7 | 9.5 | 0.73 (0.56-0.95) | 10 | 22 | 20 | 10 | 1 | |||
| vs. MVAC (n=129) | 13.2 | 14.9 | (mortality HR) | 10.1 | 8.1 | p=0.017 | 26 | 17 | 62 | 17 | 1 | |||
| Bamias 2013 | 1 yr | 1 yr | ||||||||||||
| DD-MVAC (n=63) vs. | 66 | 19 | 38 | 8.5 | 20 | 8 | 11 | 50 | 2 | |||||
| DD-GC (n=63) | 62 | 18 | 37 | 7.8 | 14 | 8 | 10 | 44 | 0 | |||||
| Loehrer 1992 | 6 yrs | 19.7 mo | 6 yrs | 19.7 mo | ||||||||||
| Leuc | Gran | |||||||||||||
| C (n=120) | 1.6 | 8.2 | p=0.002 | 1.6 | 4.3 | 1 | 0 | 1 | 1 | 0 | 0 | |||
| vs. MVAC (n=126) | 6.8 | 12.5 | 3.7 | 10 | 24 | 10 | 1 | 6 | 17 | 5 | ||||
| Mead 1998 | 1 yr | |||||||||||||
| Fever | ||||||||||||||
| CMV (n=108) | 29 | 7 | 0.68 (0.51-0.90) | 5.5 | 0.55 (0.41-0.73) | 10 | 5 | 5 | ||||||
| vs. MV (n=106) | 16 | 4.5 | p=0.0065 (Mortality HR) | 3 | p=0.0001 (Risk of progression) | 2 | 0 | 0 | ||||||
| Hillcoat 1989 | 2 yrs | |||||||||||||
| Heam | Nausea | |||||||||||||
| CM (n=53) | 8.7 | p=0.7 | 10 | 5.0 | p=0.13 | 27 | 44 | 20 | 2 | |||||
| vs. C (n=55) | 7.2 | 10 | 2.8 | 7 | 25 | 0 | 0 | |||||||
| Pizzocaro 1991 | ||||||||||||||
| Leuc | ||||||||||||||
| MVAC (n=14) | 14 | 14 | 7 | 7 | ||||||||||
| vs. MC (n=14) | 7 | 7 | 7 | 7 | ||||||||||
| Petrioli 1996 | 21 mo | G 2-4 | ||||||||||||
| Leuc | ||||||||||||||
| MVEC (n=29) | 25 | 13 | 37 | 21 | 25 | 17 | ||||||||
| vs. MVECa (n=28) | 7.4 | 9.5 | p=0.3 | 58 | 26 | 10 | 16 | |||||||
| Dogliotti (2007) | ||||||||||||||
| GC (n=55) | 64 | 12.8 | 8.3 | 35 | 31 | 20 | 4 | |||||||
| vs. GCarbo (n=55) | 37 | 9.8 | 7.7 | 46 | 38 | 26 | 11 | |||||||
| Dreicer 2004 | FACT-BL: no significant differences over time between study arms | |||||||||||||
| MVAC (n=44) | 15.4 | 8.7 | 67 | 21 | 37 | 9 | 1 | |||||||
| vs. CaP (n=41) | 13.8 | p=0.65 | 5.2 | p=0.24 | 29 | 10 | 5 | 0 | 1 | |||||
| Bellmunt 1997 | ||||||||||||||
| Stoma | ||||||||||||||
| MVAC (n=24) | 12.5 | 16 | 21 | 3 | 3 | 0 | 1 | |||||||
| vs. M-CAVI (n=23) | 21.7 | 9 | p=0.03 | 4 | 3 | 3 | 3 | 0 | ||||||
| De Santis (2012) | 4.5 yrs | 4.5 yrs | No differences between arms for changes in global QoL. Inconclusive data. | |||||||||||
| Leuc | ||||||||||||||
| GCarbo (n=119) | 7.6 | 9.3 | 0.94 (0.72-1.22) | 3.4 | 5.8 | 1.04 (0.80 to 1.35) | 53 | 48 | 45 | 9 | 3 | |||
| vs. M-CAVI (n=119) | 9.2 | 8.1 | p=0.64 | 5.0 | 4.2 | 64 | 19 | 47 | 21 | 4 | ||||
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.